<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01731236</url>
  </required_header>
  <id_info>
    <org_study_id>10-544</org_study_id>
    <nct_id>NCT01731236</nct_id>
  </id_info>
  <brief_title>CARNIVAL Study: Gut Flora Dependent Metabolism of Dietary CARNItine and Phosphatidylcholine and cardioVAscuLar Disease</brief_title>
  <acronym>CARNIVAL</acronym>
  <official_title>CARNIVAL Study: Gut Flora Dependent Metabolism of Dietary CARNItine and Phosphatidylcholine and cardioVAscuLar Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The principal goal for the study is to examine the role gut flora plays in modulating&#xD;
      metabolism of dietary carnitine and choline in humans.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The principal goal for the study is to examine the role gut flora plays in modulating&#xD;
      metabolism of dietary trimethylamine nutrients in humans. We have recently shown that dietary&#xD;
      intake of two trimethylamines abundant in animal products, carnitine and the choline group of&#xD;
      phosphatidylcholine (PC), are mechanistically linked to cardiovascular disease risk. We wish&#xD;
      to further explore the metabolism of these nutrients in humans, and to test the hypothesis&#xD;
      that the intestinal micro flora (gut flora) plays a critical role in generation of&#xD;
      metabolites from dietary carnitine and choline/PC linked to cardiometabolic disease. We&#xD;
      further hypothesize that the production of specific metabolites of carnitine and choline/PC&#xD;
      are influenced by the composition of gut flora, and these may be altered by the preceding&#xD;
      dietary patterns of the subjects. We therefore wish to test whether dietary supplementation&#xD;
      with carnitine and/or choline alters the metabolism of carnitine and choline/PC in subjects.&#xD;
      We also hypothesize that transient suppression or modulation of gut flora via short-term&#xD;
      broad spectrum antibiotic therapy, or by reconstitution of micro flora composition via&#xD;
      probiotic therapy, in healthy subjects, can alter the metabolism of carnitine and choline/PC.&#xD;
      We will also examine the impact of low dose aspirin on these pathways by examining subjects&#xD;
      before versus after taking aspirin.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">February 11, 2011</start_date>
  <completion_date type="Anticipated">June 2025</completion_date>
  <primary_completion_date type="Anticipated">June 2025</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Outcome Measure</measure>
    <time_frame>December 2017</time_frame>
    <description>Plasma levels of carnitine and multiple gut flora metabolites</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Outcome Measures</measure>
    <time_frame>December 2017</time_frame>
    <description>Alterations in plasma levels of cardio-metabolic risk factors.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Dietary Modification</condition>
  <arm_group>
    <arm_group_label>Carnitine (No antibiotics, No aspirin)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>L-Carnitine 500 mg capsule by mouth, twice daily for 2 months. No aspirin for 1 month prior to starting study and remains off aspirin during study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Choline (No Antibiotics, No aspirin)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Choline 500 mg capsule by mouth, twice daily for 2 months. No aspirin for 1 month prior to starting study and remains off aspirin during study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Antibiotics</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Antibiotics (Ciprofloxacin, Vancomycin, Metronidazole and Neomycin) Drug: Ciprofloxacin 500 mg, po, twice daily for 7 days (Other Names: Cipro)&#xD;
Drug: Metronidazole 500 mg, po, twice daily for 7 days (Other Names: Flagyl, Noritate, Rosadan, Vandazole, Flagyl ER, Vitazol)&#xD;
Drug: Vancomycin 125 mg, po, 4 times daily for 7 days (Other Names: Vancocin, Vancocin HCl, Pulvules, Vancoled, Novaplus, PremierPro Rx, Vancomycin HCl)&#xD;
Drug: Neomycin 1 gram, po, four times daily for 7 days (Other Names: Aminoglycoside)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Choline and Aspirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Choline supplement 500 mg capsule by mouth, twice daily for 2 months Drug: aspirin 81 mg by mouth, daily for 3 months (on aspirin for 1 month prior to starting study and 2 months with Choline supplementation during study)&#xD;
Other Names:&#xD;
Ecotrin, Bufferin, Ascriptin, Fasprin, Norwich Aspirin, Durlaza, Bayer Genuine Aspirin, Genacote, Bayer, Halfprin, Aspirtab, Aspir Low, Aspir-Trin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carnitine and Aspirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Carnitine supplement 500 mg capsule by mouth, twice daily for 2 months Drug: aspirin 81 mg by mouth, daily for 3 months (on aspirin for 1 month prior to starting study and 2 months with Carnitine supplementation during study)&#xD;
Other Names:&#xD;
Ecotrin, Bufferin, Ascriptin, Fasprin, Norwich Aspirin, Durlaza, Bayer Genuine Aspirin, Genacote, Bayer, Halfprin, Aspirtab, Aspir Low, Aspir-Trin</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Carnitine</intervention_name>
    <description>Group 1: Carnitine supplement for 2 months, No antibiotics, no aspirin for 3 months (1 month prior and during study)</description>
    <arm_group_label>Carnitine (No antibiotics, No aspirin)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Choline</intervention_name>
    <description>Group 2: Choline supplement for 2 months, No antibiotics, no aspirin for 3 months (1 month prior and during study)</description>
    <arm_group_label>Choline (No Antibiotics, No aspirin)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antibiotics</intervention_name>
    <description>Group 3: Carnitine or Choline for 2 months, antibiotic cocktail (Ciprofloxacin, Flagyl, Vancomycin, and Neomycin) for 1 week</description>
    <arm_group_label>Antibiotics</arm_group_label>
    <other_name>Ciprofloxacin, Flagyl, Vancomycin, and Neomycin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Choline and Aspirin</intervention_name>
    <description>Group 4: Choline supplement for 2 months plus aspirin 81 mg for 3 months (1 month prior to starting the study and 2 months during the study).</description>
    <arm_group_label>Choline and Aspirin</arm_group_label>
    <other_name>aspirin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carnitine and Aspirin</intervention_name>
    <description>Group 5: Carnitine supplement for 2 months plus aspirin 81 mg for 3 months (1 month prior to starting the study and 2 months during the study).</description>
    <arm_group_label>Carnitine and Aspirin</arm_group_label>
    <other_name>aspirin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women age 18 years or above.&#xD;
&#xD;
          -  Able to provide informed consent and comply with study protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Significant chronic illness or end-organ dysfunction, including known history of heart&#xD;
             failure, renal failure, pulmonary disease, hematologic diseases or pregnancy.&#xD;
&#xD;
          -  Active infection or received antibiotics within 2 months of study enrollment&#xD;
&#xD;
          -  Use of Over-The-Counter (OTC) probiotic within past 2 months, or ingestion of yogurt&#xD;
             within past 7 days&#xD;
&#xD;
          -  Chronic gastrointestinal disorders, or intolerance to probiotic therapy&#xD;
&#xD;
          -  Having undergone Bariatric procedures or surgeries such as gastric banding or bypass&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stanley L Hazen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 23, 2012</study_first_submitted>
  <study_first_submitted_qc>November 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2012</study_first_posted>
  <last_update_submitted>September 9, 2021</last_update_submitted>
  <last_update_submitted_qc>September 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Carnitine metabolism</keyword>
  <keyword>gut flora</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Vancomycin</mesh_term>
    <mesh_term>Ciprofloxacin</mesh_term>
    <mesh_term>Neomycin</mesh_term>
    <mesh_term>Choline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

